
Details of the "deals" are very sketchy as I pen this blog (old deal? here). However, here's what I understand. The "new deal" appears to be part of a compromise that occurred in the Senate surrounding Dorgan's Drug Reimportation amendment. Just after the Dorgan amendment was defeated, Senator Reid announced that he would support a full closure of the Donut Hole in the House/Senate Conference Committee following passage of the reform bill in the Senate. Up until Reid's statement, unlike the the House's version of the legislation, the Senate only slightly filled the Donut Hole (eliminating $500 of it). It appears to have been a "Jelly for the Donut Hole in exchange for no drug imports" deal.
Also, late yesterday, there were vague reports that the cost of closing the Donut Hole would now be borne by the Pharmaceutical Industry generating confusion over the duration of it's commitment and if it was strictly for the period over which the Donut Hole was closed. The original deal was supposed to be a 50% discount for drugs in the unclosed Donut Hole. There were also reports that the industry would pony up an additional $20 billion. Some sources said the additional $20 billion would not come from manufactures but from PBMs.
So this morning I am left with one hand on my coffee mug and the other scratching my head. Key questions on the table this morning about the "new deal"
- How long will Pharma be contributing to the Donut Hole? Until it's closed as originally thought or for years after it is closed?
- Exactly how much will Pharma contribute to the Donut Hole and/or it's closure?
- Will other industry players like PBMs be asked to ante up as well?
Updates...
- The New Republic suggests the possibility of 75% discounts in the Donut Hole.
No comments:
Post a Comment